News about "antibody-drug conjugates "

Sterling Pharma Solutions Expands UK Bioconjugation Capacity

Sterling Pharma Solutions completes a new 500L GMP manufacturing suite at its bioconjugation facility in Deeside, UK.

Antibody-Drug Conjugates | 06/10/2026 | By News Bureau

AstraZeneca Completes USD 2B Equity Investment in Summit Therapeutics

AstraZeneca has completed its USD 2 billion equity investment in Summit Therapeutics to advance ivonescimab-based cancer treatment combinations.

Antibody-Drug Conjugates | 06/10/2026 | By News Bureau

Avacta Reports Early Clinical Validation of AVA6103 in FOCUS-01 Trial

Avacta’s early FOCUS-01 data provide clinical validation for AVA6103 and support further evaluation of its pre|CISION tumour-activated PDC platform.

Antibody-Drug Conjugates | 21/09/2026 | By News Bureau |  980

Japan Approves Enhertu and Datroway for New First-Line Metastatic Breast Cancer Indications

Japan has approved new first-line metastatic breast cancer indications for Daiichi Sankyo’s Enhertu and Datroway, expanding treatment options for patients with HER2-positive and triple-negative breast cancer.

Antibody-Drug Conjugates | 17/09/2026 | By News Bureau |  420

Acepodia Receives FDA Clearance for ACE723 ADC in Advanced Liver Cancer

Acepodia’s ACE723 is designed to deliver two cytotoxic payloads to GPC3-expressing tumour cells in patients with unresectable or metastatic hepatocellular carcinoma.

Antibody-Drug Conjugates | 07/09/2026 | By News Bureau |  115

Akeso Initiates Phase 2 Trial of TROP2/Nectin-4 Bispecific ADC in Advanced Breast Cancer

Akeso has dosed the first patient in a Phase 2 study of AK146D1 combined with ivonescimab, advancing its next-generation “IO2.0 + ADC2.0” approach for advanced breast cancer.

Antibody-Drug Conjugates | 10/08/2026 | By News Bureau |  173

Iksuda Therapeutics Secures US FDA IND Clearance for Novel ADC Candidate IKS04 in GI Cancers

Phase 1 trial to evaluate first-of-its-kind CA242-targeted antibody-drug conjugate with an innovative co-administration regimen designed to improve solid tumour penetration and therapeutic efficacy.

Antibody-Drug Conjugates | 03/08/2026 | By News Bureau

Piramal Pharma Solutions Expands ADC Capabilities with Ajinomoto Bio-Pharma Services Pact

Piramal Pharma Solutions partners with Ajinomoto Bio-Pharma Services to accelerate ADC development and manufacturing, enabling access to AJICAP technology.

Antibody Drug Conjugates | 20/04/2026 | By News Bureau |  222

Mycenax and Spera Pharma Partner to Streamline ADC Drug Substance and Drug Product Manufacturing Services

The partnership aims to speed up market entry for biopharma firms by combining Mycenax's biologics expertise with Spera Pharma’s high-potent fill-finish capabilities, offering an integrated, cost-effective ADC development platform.

Antibody-Drug Conjugates | 15/09/2025 | By Dineshwori |  382

Veranova's Devens Site Clears FDA Inspection with Zero Observations

Veranova's Devens site has successfully completed a routine current Good Manufacturing Practice (cGMP) surveillance inspection by the Food and Drug Administration (FDA).

Antibody-drug Conjugates | 14/08/2025 | By Dineshwori |  391